Quote:Recent data from the US also suggests that the Johnson & Johnson Janssen vaccine - which also uses an adenovirus entry system - raises the risk of GBS to similar levels as the AstraZeneca jab.

Lead author Prof Michael Lunn (UCL Queen Square Institute of Neurology) said: “At the moment we don’t know why a vaccine may cause these very small rises in GBS.

“We know that Pfizer and Moderna don’t cause BDS but Johnson & Johnson and AstraZeneca do and the only commonality link is an adenovirus vector,” added Prof Lund.

“Johnson & Johnson is not the same one because they use a human adenovirus but it’s similar and the implications are broad because adenoviruses are used in quite a lot of vaccines and genetic therapies.

“The benefits from these vaccines and drugs are huge and the risk is tiny and there aren’t that many viral vectors you can use, but it’s good that the public are aware of the risks.

“And theoretically, if we know what virus is causing GBS, we can turn it off and we might be able to prevent disease progression.”
The Telegraph

Quote:Pfizer Bets On Medical Cannabis With $6.7 Billion Acquisition

Pfizer is to enter the medical cannabis industry betting on a promising cannabinoid-based bowel disease treatment.

Arena Pharmaceuticals is a biotech company with one pipeline dedicated to cannabinoid-type therapeutics. The core of its cannabis operation consists of Olorinab (APD371), an investigational, oral, full agonist of the cannabinoid type 2 receptor (CB2), which aims to treat patients with diseases affecting the stomach and intestine. As Arena's website states, Olorinab is an investigational drug and is not currently approved for use by any health authority.

"We're delighted to announce Pfizer's proposed acquisition of Arena, recognizing Arena's potentially best in class S1P molecule and our contribution to addressing unmet needs in immune-mediated inflammatory diseases," he said.